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April 2, 2013:1461–8vs. 100%) and baseline estimated glomerular filtration rate (68  43
l/min/1.73 m2 vs. 102  44 ml/min/1.73 m2), which were signif-
cantly worse in the ADHF versus control group. Nevertheless, there
ere no significant differences between groups in age, body mass
ndex, or several comorbidities (i.e., diabetes mellitus, chronic obstruc-
ive pulmonary disease, active smoking) theorized to result in altera-
ions in the exhaled metabolome.
After written informed consent was obtained, exhaled breath
amples were collected within 24 h of hospital admission and
ollowing an 8-h fast and before the administration of morning
harmacotherapy. Samples were collected after tap water mouth rinse
o minimize and standardize the contribution of the aerodigestive
ract. Patients provided a single exhaled vital capacity into a sterile
outhpiece while attempting to maintain an exhaled pressure of 15
illibars. All breath analyses were performed within 2 h of collection
sing a VOICE200 SIFT-MS instrument (Syft Technologies,
hristchurch, New Zealand). Pre-specified quantitative assessment of
cetone and pentane was performed using the SIFT-MS technique.
ample collection was well tolerated even among patients with disease
everity warranting intensive care unit admission and invasive hemo-
ynamic monitoring. Confirming previous reports (3,4), we observed
ncreased exhaled acetone (median [interquartile range]: 811 [256 to
974] ppb vs. 187 [115 to 572] ppb, p  0.01) and pentane (40 [20
o 74] ppb vs. 22 [14 to 36] ppb, p  0.03) levels in ADHF versus
ontrol groups. In addition, mass scanning of ion products for H3O
,
2
, and NO from 14 to 200 atomic mass units was performed, and
stepwise variable selection was used to identify 5 ion peaks that were
incorporated into a canonical discriminant analysis model that suc-
cessfully distinguished ADHF from control patients (2 log likeli-
hood 0.038; Wilks’ Lambda 0.102 [p  0.0001]) (Fig. 1). This
“breathprint” was then tested in an independent validation cohort of
36 consecutive ADHF subjects with identical enrollment criteria to
the derivation cohort. The discriminant analysis model correctly
classified all subjects with no misclassifications (Fig. 1).
The exhaled metabolome is a temporally dynamic complex
mixture, and therefore breath analysis is highly susceptible to the
confounding effects of timing and context of sample collection. In
addition, methods of metabolomic data analysis (e.g., data reduc-
tion techniques) are still being formalized and will need to be
refined to facilitate reproducibility and generalizability of future
studies. Results of this study are limited by the small sample size,
and larger prospective studies are needed to validate these results.
Nevertheless, our findings demonstrate the feasibility of single
exhaled breath analysis in ADHF. In addition, we validated the
previously reported alterations in acetone and pentane VOC
concentrations in ADHF, and provided pilot evidence to support
the hypothesis that a unique ADHF breathprint exists using
SIFT-MS technology. Once a specific VOC or panel of VOCs is
identified, highly sensitive and specific solid-state sensors can be
integrated into portable detectors. Like conventionally available
exhaled breath sensors, the promise of this technology lies in the
potential for point-of-care and ambulatory monitoring and screen-
ing. Future studies in exhaled breath metabolomics are needed to
accelerate progress in the field of cardiovascular medicine.
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Letters to the Editor
Colchicine After Pulmonary Vein
Isolation: Is Inflammation the
New Anti-Arrhythmic Target
We have read with interest the study by Deftereos et al. (1) aimed
at testing the role of colchicine in preventing atrial fibrillation (AF)
recurrences in patients with recurrent paroxysmal AF who under-
R1465JACC Vol. 61, No. 13, 2013 Correspondence
April 2, 2013:1461–8went catheter ablation. The rationale for such a study is based on
accumulative evidence indicating that inflammatory pathways are
of significance in AF. After both catheter ablation and cardiac
surgery, leukocytosis and proinflammatory cytokines have been
directly related to the incidence of post-procedural AF (2,3). As
the cytokines increase, the risk of AF concomitantly increases.
Therefore, colchicine, a potent anti-inflammatory agent, may have
a relevant role in preventing inflammatory-facilitated AF after
catheter ablation.
The study shows an interesting correlation between the bio-
marker levels and the rate of AF recurrences. However, inflam-
matory biomarkers also have been correlated with the amount of
energy delivered (2). Therefore, the extensive ablation strategy
performed in the present study (50% of patients underwent
complex atrial fractionated electrogram ablation) may have affected
the proinflammatory state after ablation, which may have overes-
timated the role of colchicine in this series compared with
less-extensive AF ablation procedures. Furthermore, the role of
complex atrial fractionated electrogram ablation in paroxysmal AF
is at least controversial, which makes the results less relevant to
conventional pulmonary vein isolation in patients with paroxysmal
AF and mild cardiac disease (4). In addition, although some
evidence suggests that inflammation might be a causative agent for
AF (5), a substantial body of evidence supports that AF and
inflammatory pathways have a bidirectional relationship (6). Thus,
other substrates such as persistent AF, with both higher baseline
levels of biomarkers and the need for more extensive atrial ablation
(4,7), might benefit from using colchicine to prevent AF recur-
rences after the procedure.
The short-term follow-up precludes extrapolating the results to
longer periods, despite the short-term concomitant proinflammatory
state after ablation. As reported in the 5A Study at the 6-month
follow-up (8), short-term use of antiarrhythmic drugs after paroxys-
mal AF ablation reduced early recurrence of atrial arrhythmias.
However, early use of antiarrhythmic drugs did not prevent recur-
rences at 6 months. Therefore, similar results might be observed after
6 months of colchicine. In addition, a significantly higher number of
patients receiving colchicine reported diarrhea compared with patients
receiving placebo, and up to 12.3% discontinued the drug. Colchicine
may have deteriorated the quality of life of patients in the colchicine
group, despite the potential benefit of reducing the arrhythmia
burden. Thus, it seems reasonable to predict that longer periods under
colchicine will show similar rates of secondary effects, which makes it
necessary to include a disease-specific quality of life questionnaire in
future trials assessing the role of colchicine over longer periods of
follow-up.
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Reply
We thank Dr. Filgueiras-Rama and colleagues for their interest in
our work. We agree that 3 months of follow-up are not enough to
demonstrate the clinical efficacy of an intervention against atrial
fibrillation (AF) recurrence. This is exactly why the aim of our
paper, as clearly stated in the introduction of our published paper
(1), was not to demonstrate long-term clinical efficacy. The goal
was rather to prove the principle that an anti-inflammatory
treatment, which can be administered safely for a relatively
prolonged period of time (and only colchicine has these charac-
teristics among existing anti-inflammatory treatment options) can
lead to a reduction in the rate of AF recurrence within the time
limits during which inflammatory processes are perceived to play a
role in post-ablation AF recurrence (i.e., a few weeks to 2 to 3
months). To study long-term clinical efficacy, we have an extended
protocol underway and 1-year results will be published in due time.
These results also will include quality-of-life assessment measures.
We hope that this will address the authors’ concerns regarding the
effect of colchicine treatment on quality of life. However, it should
be noted that, according to our experience, most patients are more
frustrated and disappointed by a recurrence of their arrhythmia (by
which they were, after all, troubled enough to consent to undergo
an interventional procedure) than by mostly mild and easily
manageable gastrointestinal side effects.
